Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Persistent heterogeneity … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective

Artikel i vetenskaplig tidskrift
Författare Z. Sumnik
A. Szypowska
V. Iotova
N. Bratina
V. Cherubini
Gun Forsander
S. Jali
J. F. Raposo
G. Stipančic
A. Vazeou
H. Veeze
K. Lange
N. Papo
D. Kownatka
S. Lion
P. Gerhardsson
T. Kalina
B. Rami-Merhar
J. Svensson
R. Hanas
M. Knip
M. Witsch
R. Verkauskiene
S. Todorovic
P. Toth-Heyn
M. Ng
J. Pelicand
K. Podolakova
B. Timar
K. Casteels
R. Cordona Hernandez
H. Hoey
Publicerad i Pediatric Diabetes
Volym 20
Nummer/häfte 4
Sidor 434-443
ISSN 1399-543X
Publiceringsår 2019
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för pediatrik
Sidor 434-443
Språk en
Länkar dx.doi.org/10.1111/pedi.12833
Ämnesord children, diabetes technology, reimbursement, type 1 diabetes
Ämneskategorier Diabetologi, Pediatrik

Sammanfattning

Background: Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. Methods: The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. Results: We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. Conclusions: Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement. © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?